What We're Reading: Page 302
Industry reads hand-picked by our editors
Apr 25, 2017
-
Reuterds
NASH: The next untapped pharma market gives investors many options
-
MIT Technology Review
Immunotherapy pioneer James Allison has unfinished business with cancer
-
The Wall Street Journal
Novartis tests new Alzheimer's drug on people who don't have the disease
-
Bloomberg
Billionaire doctor's $11,000 cancer test has few takers so far
Apr 24, 2017
-
Financial Times
Sanofi plays down need for pharma deals
-
The Guardian
WHO, Pfizer seek acceleration of global access to vaccines
-
The Wall Street Journal
QuintilesIMS in deal to use Salesforce.com’s cloud technology
-
Forbes
Hiding data and other criticisms of big pharma
Apr 21, 2017
-
Bloomberg
Biotech M&A falls off as Trump dashes hopes of a new pharma boom
-
The Guardian
Sanofi epilepsy drug linked to over 4,000 child deformities
-
Chicago Tribune
$3 million awarded to widow who sued pharmaceutical firm over husband's suicide
-
Kaiser Health News
With drug costs in crosshairs, health firms gave generously to Trump’s inauguration
Apr 20, 2017
-
Bloomberg
Google’s health moonshot comes back to Earth
-
Reuters
Gates backs big pharma push to wipe out tropical diseases
-
Business Insider
We just got a better idea of how much drug companies rely on price hikes, and it doesn't look good
-
Forbes
Meet the top VC in a race to find his own Parkinson's cure
-
Voice of America
Overcoming opioids: The quest for less addictive drugs
Apr 19, 2017
Apr 18, 2017
-
NPR
Nonprofit working to block drug imports has ties to pharma lobby
-
Business Insider
The makers of a lethal-injection drug have become leaders in Arkansas' death-penalty battle
-
Xconomy
Cancer drugmaker G1 Therapeutics makes IPO Pitch to Wall Street
-
Forbes
The billionaire and the drug price-fixing scandal
Apr 17, 2017
-
Forbes
Apple and Google, the next big pharma
-
The Sacramento Bee
Can California’s ‘right to try’ law help save terminal patients?
-
The Guardian
Scarcity of meningitis vaccine persists as epidemic worsens
-
MarketWatch
Pharma companies are seeking a new treatment — for the backlash against high drug prices
Previous
